Cellares suffers financial blow as BMS ends collaboration
Bristol Myers Squibb (BMS) ended a $380M partnership with Cellares, citing manufacturing requirements for its CAR-T therapy Breyanzi. Cellares disputes BMS's claims and plans to restructure, focusing on core products. BMS confirmed the termination, while Cellares reassured customers about its strong portfolio. The impact on Cellares' international expansion is uncertain. BMS recently faced a setback with its Krazati therapy.
How this was made
The 30-second read
Why it matters
The loss of a major manufacturing contract could affect BMY's short‑term cost structure and raise concerns about supply chain stability for its CAR‑T product Breyanzi.
Market read
Primary disclosure of a large contract termination with material financial impact on a major US pharma, relevant for traders monitoring BMY.
What to watch
Cellares' ongoing collaborations with other biotech firms may mitigate the impact on BMY's pipeline continuity.
Background
The article reports the first public disclosure of BMS ending a $380 M partnership with Cellares, a CDMO, leading to restructuring at Cellares.
Ticker impact
Bristol Myers Squibb (BMY) terminated a $380 million manufacturing partnership with CDMO Cellares for its CAR‑T therapy Breyanzi.
Downward pressure on BMY stock in the near term.
A $380 M deal loss is material; investors may reassess BMY's manufacturing capabilities and cost structure.
Market effects
Highlights supply‑chain risks for CAR‑T manufacturers and may prompt peers to reassess CDMO contracts.
Potentially affects US biotech sector sentiment, with limited immediate impact on Asian markets.
Moderate, as BMY is a large-cap US pharma; the news may influence broader pharma valuations.
Counterpoint
BMY may have strategic reasons for the split, possibly shifting to a more cost‑effective or higher‑capacity partner, which could improve margins long‑term.
Key entities
- CompanyBristol Myers Squibb
US‑listed pharmaceutical company (ticker BMY) terminating the partnership.
- CompanyCellares
Private CDMO losing the partnership.
